|
Double Blind Studies -- Have shown significant decreases in degenerative liver damage in patients with chronic liver disease (cirrhosis of the liver) while using Liver Support Formula in as few as 30-90 days.
Liver Support Formula is an extremely effective product for detoxifying the liver, normalizing liver metabolism and preventing further damage, due to internal and external toxins such as alcohol cigarettes and environmental poisons.
A COMPARATIVE STUDY BETWEEN A COMPLEX OF FLAVONOIDS & POLYPHENOLS (CREATED FROM EXTRACTS OF ARTICHOKE AND SARSAPRILLA) AND A PLACEBO IN ALCOHOL RELATED LIVER DISEASE
DECEMBER 12 1998
In a previous study, completed over two years ago in this same hospital (see followed First Double Blind study ), an extract of artichoke (Cynara Floridanum) and sarsaparilla (Smilax Aristolochiaefolia) was evaluated in addressing the symptoms related to alcoholic liver disease. This study was accomplished over a fifteen-day period with exceptional results. Because of these results noted over a very short period of time, the hospital researchers were anxious to set up the same study over a longer period (30 days). Please refer to the July 3, 1996, study for descriptions of symptoms and study parameters.
Results of this study are as follows:
|
ASCITES |
|
A 72.38% reduction of the accumulation of serious abdominal fluid was noted in the treated group. The placebo saw a 6.35% increase in abdominal fluid.
|
ENCEPHALOPATHY |
|
A 66.08% reduction of symptoms related to encephalopathy was noted in the treated group. The placebo group saw a 12.24% increase in these symptoms.
|
HEPATOMEGALY |
|
The treated group experienced a 93.33% reduction in enlarged livers. In the placebo group their livers continued to enlarge by another 7.14%.
|
|
SPLENOMEGALY |
An 88.40% reduction in spleen enlargement was noted with the treated group. The placebo group worsened by 11.54%.
|
|
WEAKNESS |
The treated group noted a 73.64% increase in strength. There was a decrease in muscle strength by 7.41% in the placebo group.
|
|
PERIPHERAL EDEMA |
Edema in the extremities of the treated patients decreased by 48.21%. There was no change in the placebo group.
|
|
HEMORRHAGES |
The treated group noted a 100% decrease in capillary hemorrhaging in the skin, gums, and nasal membranes. The placebo group saw an increase of 28.57% in hemorrhaging.
|
|
ANOREXIA |
Loss of appetite decreased in the treated group by 76.98%. The placebo group noted a decrease of 3.70%.
|
|
ABDOMINAL WALL VEINS |
The treated group experienced a 60.62% decrease in tortuous veins in the abdomen related to ascites. The placebo group saw a 3.33% decrease.
|
|
PALMAR ERYTHEMA |
The treated group noted a 26.67% decrease in red and swollen palms. In the placebo group there was no change.
|
|
TELANGIECTASIA |
A 60.00% reduction in vascular lesions was noted in the treated group. A 3.33% reduction was seen in the placebo group.
|
|
TOTAL BILIRUBIN |
The treated group noted a reduction of total bilirubin by 38.95%. The placebo group increased by 5.68%.
|
|
ALKALINE PHOSPHATASE |
The treated group obtained 25.91% reduction in alkaline phosphates. There was an 11.69% increase in the placebo group.
|
|
SERUM GLUTAMIC OXALCETIC TRANSAMINASE (SGOT) |
The treated group noted a decrease of 23.83% in SGOT levels. The placebo group experienced a worsening of 11.71%.
|
|
PROTHROMBIN TIME |
A 42.00% reduction in clotting time was noted with the treated group. An increase in clotting time was noted in the placebo group of 6.60%.
|
|
SERUM ALBUMIN |
An increase of 37.27% in serum albumin was noted in the treated group. There was a decrease in the placebo group of 1.95%.
|
|
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) |
|
The treated group noted a reduction of 23.79% in GGT. The placebo group experienced an increase of 9.92%.
|
DR.CHARLES COCHRAN
NTERPRETATION OF RESULTS OBTAINED IN A DOUBLE-BLIND TEST MADE IN THE GENERAL HOSPITAL MEXICO WITH THE PRODUCT LIVER SUPPORT ON PATIENTS HAVING CHRONIC ALCOHOLIC HEPATIC DISEASE.
In order to analyze carefully the results of this study, it is necessary to know the importance of the two clinical and laboratory parameters intervening in the calculations of Orrego and Maddrey Indexes.
We will compare the results of parameters, the placebo and the Liver Support groups on both indexes. The results are presented as percentages of recovery and are obtained from the data obtained from each group of 30 patients; we will get an average of those results at the beginning and at the end of the study. Both averages will give us a final average of recovery compared to the initial values. This way we may demonstrate the effectiveness of Liver Support.
DEFINITION AND RESULTS OF PARAMETERS
|
ASCITES |
|
Effusion and accumulation of serous fluid in the abdominal cavity. It was observed 28.8% of reduction of ascites. In the placebo group there was no change.
|
|
ENCEPHALOPATHY |
A degenerative disease of brain. Hepatic encephalopathy – a condition usually occurring secondarily to advanced disease of the liver. It is marked by disturbances of consciousness which may progress to deep coma (hepatic coma) psychiatric changes of varying degree flapping tremor and fetor hepaticas. Called also portal-systemic encephalopathy. With Liver Support there was a 34.55% reduction on encephalopathy. The placebo group a 5.5% of reduction was observed.
|
|
SPLENOMEGALIA |
Enlargement of the spleen. An 18.18% of reduction in the Liver Support group and a 55% reduction in the placebo group was observed.
|
|
WEAKNESS |
Lacking physical strength or vigor asthenia atony cardiasthenia enervation fatigue and lassitude. The group of Liver Support obtained 83.45% diminishing of weakness. There was no change in the other group.
|
|
PERIPHERAL EDEMA |
|
A condition in which the body tissues contain an excessive amount of tissue fluid. In the Liver Support group 11.10% of reduction was observed. The placebo group has 0.69% of reduction.
|
|
HEMORRHAGES Bleeding. |
This was one of the most important benefits because the group of Liver Support had a reduction of 89.41% and the placebo had 31% reduction.
|
|
ANOREXIA |
Loss of appetite. Seen in depression malaise commencement of fevers and illnesses also in disorders of alimentary tract especially of stomach and as a result of alcoholic excesses drug addiction or many medicines. Anorexia was diminished 86.07% in the Liver Support group. There was no change in the other group.
|
|
TOTAL BILIRUBIN LEVEL |
The Liver Support group obtained 25.11% reduction whereas the placebo group had a 7.2% increase.
|
|
OGT |
(Oxalacetic Glutamic Transaminase). It is distributed all over the tissues especially in the heart and liver less amounts are found in the spleen pancreas kidneys lungs and brain. Any lesion of a tissue leads to the secretion of this enzyme to the blood stream. The activity of OGT is risen under hepatic necrosis cirrhosis or hepatic metastasis. In those patients who received Liver Support this level diminished 22.56%in only 15 days of treatment and in the placebo group diminished 8.51%.
|
|
PROTHROMBINE TIME |
|
A test of clotting time made by determining the time for clotting to occur after thromboplastin and calcium are added to decalcified plasma. There was 30.82% diminishing for Liver Support patients whereas placebo group increased 1.25%.
This is very important data because it means that Liver Support helps the healing of wounds faster.
|
|
SERUM ALBUMIN |
One of a group of simple proteins widely distributed in tissues; it is found in the blood. Low levels of albumin in blood plasma are associated with a pathologic condition of the liver. With Liver Support it was obtained an average of 8.85% of increase. The placebo had 5.35% increase.
|
[Go Back To Top]
Questions or comments?
info@extremehealth-usa.com
|
[Home]>
liver>Double Blind Studies
